Richmond VA Medical Center, Richmond, VA

Is Richmond VA Medical Center registered with the FDA as a 503B outsourcing facility?

No matching record found in FDA’s registered outsourcing facility list (updated Nov 6, 2026) on Nov 15, 2026, searching by name and location. FDA’s compounding inspections and actions page labels it a 503A facility.

Does Richmond VA Medical Center hold a Virginia pharmacy license?

State pharmacy license records for Virginia are not checked: the Department of Health Professions’ license lookup is an interactive search form, which this index does not use. This index reads only that state’s board actions.

Has Richmond VA Medical Center had a state board action or FDA letter?

FDA letters: no matching record found on FDA’s compounding inspections and actions page (current as of Oct 22, 2026, covering 2019 on) on Nov 15, 2026; the page lists 1 Form 483 (May 12, 2026) for Richmond VA Medical Center. State board actions: no Virginia Board of Pharmacy action under this exact name and city was found in the Virginia Department of Health Professions’ list of Board of Pharmacy case decisions from the last 90 days (actions dated Aug 17, 2026 to Nov 15, 2026) on Nov 15, 2026.

FDA registers 503B outsourcing facilities; state boards of pharmacy license pharmacies, including 503A compounding pharmacies, and keep their own disciplinary records. Neither FDA list says which drugs a pharmacy makes.

Names in FDA records
Richmond VA Medical Center
Location
Richmond, VA
Type as FDA labels it
503A
FDA 503B list
No matching record found
Form 483s on FDA’s actions page
1
Warning letters on FDA’s actions page
0
Latest action on that page
May 12, 2026
FDA Data Dashboard inspections
11 inspections: 5 VAI, 6 NAI; 1 published Form 483
Form 483 text on this page
1 Form 483, 8 observations
State board records
Not checked (license records); board actions matched: 0

FDA inspections and letters

FDA’s compounding inspections and actions page (current as of Oct 22, 2026) lists this pharmacy as Richmond VA Medical Center, a 503A facility, with 1 dated action.

Document
May 12, 2026Form 483483 Issued 05/12/2026fda.gov

A Form 483 lists investigator observations, not a final FDA determination.

FDA inspection classifications and published Form 483s

The FDA Data Dashboard, read Nov 15, 2026, lists Richmond VA Medical Center, Richmond, VA (FEI number 1174302), matched to this page by exact name, city and state. It lists 11 inspections: 5 VAI, 6 NAI at that site, newest first, with FDA’s classification as worded on the dashboard. Dashboard firm profile.

Inspection endedClassificationProject area and product typeFEIInspection ID
Nov 30, 2023No Action Indicated (NAI)Blood and Blood Products (Biologics)11743021225014
Apr 21, 2022No Action Indicated (NAI)Vaccines and Allergenic Products (Biologics): No Action Indicated (NAI); Blood and Blood Products (Biologics): No Action Indicated (NAI)11743021168190
Jan 25, 2019No Action Indicated (NAI)Blood and Blood Products (Biologics)11743021078446
Jul 19, 2018Voluntary Action Indicated (VAI)Drug Quality Assurance (Drugs)11743021060421
Apr 11, 2017No Action Indicated (NAI)Blood and Blood Products (Biologics)11743021012428
Oct 25, 2016Voluntary Action Indicated (VAI)Drug Quality Assurance (Drugs)1174302989761
Aug 19, 2015Voluntary Action Indicated (VAI)Blood and Blood Products (Biologics)1174302939570
Mar 11, 2015Voluntary Action Indicated (VAI)Drug Quality Assurance (Drugs)1174302917989
Jun 14, 2013No Action Indicated (NAI)Blood and Blood Products (Biologics)1174302836652
May 20, 2011No Action Indicated (NAI)Blood and Blood Products (Biologics)1174302725052
Aug 11, 2009Voluntary Action Indicated (VAI)Blood and Blood Products (Biologics)1174302610926

Form 483s FDA has published for this site

FDA classifies each inspection when it is closed: No Action Indicated (NAI) means no objectionable conditions were found or they did not justify further action; Voluntary Action Indicated (VAI) means objectionable conditions were found but FDA is not prepared to take or recommend regulatory action; Official Action Indicated (OAI) means FDA recommended regulatory or administrative action. A classification is FDA’s, not a finding by this site. The dashboard lists inspections once FDA has classified them, from fiscal year 2009 on, so a recent inspection may not appear yet.

Form 483 observations

A Form 483 lists an FDA investigator’s observations at the end of an inspection. It is not a final FDA determination. In FDA’s words: “The FDA Form 483 does not constitute a final Agency determination of whether any condition is in violation of the FD&C Act or any of its relevant regulations.” (FDA Form 483 FAQ). The firm may have answered or corrected these points; a response is not shown here unless FDA lists one.

FDA’s published Form 483 for this site has 8 numbered observations in all. Each observation is quoted from the PDF as FDA numbered it. Names of people on the form are not shown. What a Form 483 is; all 483s in this index.

Inspection May 5, 2026 to May 12, 2026: 8 observations

Firm on the cover
Richmond VA Medical Center, 1201 Broad Rock Blvd, Richmond, VA 23249-0001
FEI number
1174302
Establishment type on the cover
Producer of Sterile Drug Products
FDA district office on the cover
11155 Dolfield Boulevard, Suite 117 Owings Mills, MD 21117
Matched to this page by
FEI number on the cover; linked from actions page, Data Dashboard
FDA document
Read the full 483 (PDF on fda.gov)

Observation 1

Personnel were observed conducting aseptic manipulations where the movement of "first air" in the ISO 5 area is blocked or disrupted.

Specifically,

On 05/05/2026, a compounding technician was observed preparing the following prescription in Buffer Room lH-ll0A:

R R X <Redacted B4> TPN, 2000 mL IV Bag

During the preparation of RX# <Redacted B4> the following deficiency was observed:

While injecting components into the 2000mL IV bag, the technician's hand placement was observed blocking the bag port and needle. The technician's hands were positioned in a manner that obstructed the unidirectional first air between the HEPA filter face and the critical work surface, thereby compromising the sterility assurance of the critical area.

Observation 2

Personnel performed aseptic manipulations with exposed hair or skin.

Specifically,

a. The compounding technician was observed leaning into the ISO 5 Laminar Airflow Workbench (LAFW). with exposed skin around the eyes and forehead while performing aseptic manipulations of <Redacted B4> TPN, 2000 mL IV Bag, increasing the risk of contamination to the critical work surface.

(LAFW). with exposed skin around the eyes and forehead while perfo1ming aseptic manipulations of 5 F.){# ~b) ( ). (b) (7)(C~ - TPN, 2000 mL IV Bag, increasing the 1isk of contamination to the critical work surface.

b. The compounding technician's upper torso was observed physically introduced into the ISO 5 LAFW environment during aseptic manipulations. As gowns are not sterile, the introduction of the technician's torso into the ISO 5 environment represents an independent contamination risk, regardless of the gown's condition. This action resulted in the technician's body blocking and disrupting the unidirectional HEPA-filtered airflow (first air) over the critical work surface, compromising the sterility assurance of the critical area.

Observation 3

Lack of disinfection of equipment at each transition from areas of lower quality air to areas of higher quality air.

Specifically,

On 05/05/2026, compounding technician was observed preparing the following prescription in Sterile Buffer Room lH-ll0A:

• RX# <Redacted B4> TPN, 2000mL IV bag

During TPN compounding, the technician was observed operating a <Redacted B4> scanner connected to the <Redacted B4> TPN Compounder Computer while entering multiple times into and out of the ISO 5 LAFW without disinfecting the scanner or gloves each time. Additionally, the technician was observed touching the TPN formulation via the <Redacted B4> (Control Panel (Version <Redacted B4>) touchscreen on the <Redacted B4> TPN Compounder Computer touchscreen, which is located outside of the ISO 5 LAFW, then going back into the ISO 5 hood to perform aseptic manipulations without disinfecting their gloves.

Observation 4

Personnel were observed moving quickly in a critical area or in an area immediately adjacent to a critical area likely causing disruption of unidirectional airflow.

Specifically,

On 05/05/2026, compounding technician was observed preparing the following prescriptions in Buffer Room l H-ll0A:

• RX# <Redacted B4> Remicade (Infliximab) 500mg/0.9%NS, 250mL IV bag

The compounding technician was observed moving quickly within the ISO 5 LAFW workspace during aseptic manipulations, disrupting unidirectional airflow and increasing the risk of introducing lesser-quality air into the ISO 5 critical area.

Observation 5

Use of a disinfectant in a manner insufficient to achieve adequate levels of disinfection.

Specifically,

On 5/6/2026 during <Redacted B4> cleaning operations, cleaning performed within the ISO 5 classified laminar airflow hood (LAFH), cleaning procedures were found to be inadequate in the following respects:

a. A compounding technician was observed wiping the interior surfaces of the ISO 5 LAFH without using overlapping wipe passes during the cleaning procedure. The absence of overlapping strokes resulted in visible gaps in surface contact, with some interior surface areas visibly not contacted or wetted by the disinfectant wipe.

b. The compounding technician was observed using a back-and-forth scrubbing motion while wiping the interior surfaces of the ISO 5 classified LAFH, rather than the required unidirectional wiping technique potentially spreading contaminants to previously cleaned areas and negating the effectiveness o fthe disinfection process.

Observation 6

Use of a sporicidal agent in the facility's ISO 5 areas was improper.

Specifically,

The compounding technician was observed performing the <Redacted B4> cleaning of the ISO 5 classified laminar airflow hoods and ISO 7 classified buffer room. The technician applied a wetted sterile wipes treated with sterile <Redacted B4> (manufactured by <Redacted B4> to the <Redacted B4> ) workbench and the <Redacted B4> and <Redacted B4> or surfaces of the laminar airflow hoods. Following application, all treated surfaces were observed to air-dry within a couple of seconds. This is inconsistent with the sterile <Redacted B4> manufacturer's <Redacted B4> specified dwell time of <Redacted B4> for sporicidal effect..

r17

Observation 7

Failure to appropriately and regularly clean and disinfect or sterilize equipment located in the ISO 5 area.

Specifically,

A <Redacted B4> light fixture housing in the ISO 5 laminar flow hood (LFH) is not properly seated, creating a gap between the housing and the surrounding surface. This gap constitutes a hard-to-clean area that may harbor particulate matter and microbial contamination, posing a risk to product quality.

Observation 8

Smoke studies were not performed under dynamic conditions.

Specifically,

The smoke study videos for the pharmacy's <Redacted B4> laminar airflow workbenches (LAFWs) and <Redacted B4> biological safety cabinets (BSCs) did not demonstrate manipulations or conditions representative of the dynamic processes used in the compounding of sterile preparations; therefore, the studies were not conducted in a manner that adequately replicates the range, complexity, or pace of actual compounding operations performed at these workstations. As a result, the studies failed to verify unidirectional airflow within the ISO 5 classified area is sufficient to protect critical sites during representative aseptic manipulations. Additionally, the volume and/or density of smoke used during these studies was inadequate to sufficiently visualize airflow patterns and identify potential turbulence or contamination risks within the ISO 5 area.

State board of pharmacy records

State pharmacy license records for Virginia are not checked: the Department of Health Professions’ license lookup is an interactive search form, which this index does not use. This index reads only that state’s board actions. Board actions source.

What this covers: Board of Pharmacy case decisions the Department of Health Professions lists as entered in the last 90 days, worded as it gives them. Older decisions are reachable only through a search form, which this index does not use, so only that 90-day window is checked. The orders themselves sit behind a disclaimer form and are not linked. Virginia pharmacy licenses are not checked. Actions in the data are dated Aug 17, 2026 to Nov 15, 2026.

This page restates FDA’s lists and state board of pharmacy records. A Form 483, letter or board action is not a finding by this site, and a missing record is not a finding either way. A state license is matched only on the same name, city and state. Follow each link for the original document. Report an error or add a company response.

Sources

Records last pulled Nov 15, 2026. Every entry links to the original public record.